已收录 268921 条政策
 政策提纲
  • 暂无提纲
Acetaminophen (APAP) hepatotoxicity-Isn't it time for APAP to go away?
[摘要] Acetaminophen (APAP) is the most commonly used drug for the treatment of pain and fever around the world. At the same time, APAP can cause dose-related hepatocellular necrosis, responsible for nearly 500 deaths annually in the United States (US) alone, as well as 100,000 calls to US Poison Control Centers, 50,000 emergency room visits and 10,000 hospitalisations per year. As an over-the-counter and prescription product (with opioids), APAP toxicity dwarfs all other prescription drugs as a cause of acute liver failure in the US and Europe, but it is not regulated in any significant way. In this review the ongoing controversy surrounding the proper role for this ubiquitous pain reliever: its history, pathogenesis, clinical challenges in recognition and management, and current regulatory status are highlighted. A new solution to a 50-year-old problem is proposed. (C) 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
[发布日期] 2017-12-01 [发布机构] 
[效力级别]  [学科分类] 
[关键词] Acetaminophen;Hepatotoxicity;APAP [时效性] 
   浏览次数:2      统一登录查看全文      激活码登录查看全文